CD274 and small cell lung carcinoma: Similarly, the CheckMate 331 trial showed no survival benefit of nivolumab over chemotherapy in relapsed SCLC when stratified by PD-L1 combined positive score at a cutoff of 1% (Spigel et al., 2021).